Investing.com -- Shares of Guardant Health (NASDAQ:GH) have increased by 5.0% in premarket trading Tuesday following the company’s announcement that its Guardant Reveal test for colon cancer has been granted expanded Medicare coverage.
The company reported that Palmetto GBA, a Medicare administrative contractor, has extended coverage for the test. This allows for the monitoring of disease recurrence in patients with colorectal cancer (CRC), who have undergone curative intent therapy.
The company stated that this development marks an expansion from the previous Medicare coverage. Prior to this, Medicare coverage for the Guardant Reveal test was limited to CRC testing in the early post-surgical setting only. T
he expansion of coverage now allows for more comprehensive monitoring of CRC patients.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.